Top Markets
#1 MarsCoin MarsCoin +37.64%
#2 Palladium Network Palladium Network +27.94%
#3 Siren Siren +26.04%
#4 Status Status +24.20%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +15.19%
#6 BankrCoin BankrCoin +15.09%
#7 ICON ICON +15.04%
#8 Useless Coin Useless Coin +11.93%
#9 Ankr Network Ankr Network +11.88%
#10 Bedrock Bedrock +11.87%
Coin of the day
MarsCoin MarsCoin
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
TaiGen Biopharmaceuticals Holdings Limited TaiGen Biopharmaceuticals Holdings Limited

TaiGen Biopharmaceuticals Holdings Limited

4157
Classifica tra le azioni #18388
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm... TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
Prezzo delle azioni
$0.28078542
Capitalizzazione di mercato
$199.87M
Variazione (1 giorno)
-0.34%
Variazione (1 anno)
-10.19%
Paese
TW
Scambia TaiGen Biopharmaceuticals Holdings Limited (4157)

Categoria

Healthcare
Rapporto P/B per TaiGen Biopharmaceuticals Holdings Limited (4157)
Rapporto P/B al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di TaiGen Biopharmaceuticals Holdings Limited, il rapporto P/B attuale (TTM) è 0. Alla fine del 2026, era pari a 0.
Storico del rapporto P/B per TaiGen Biopharmaceuticals Holdings Limited da 2026 a 2026
Rapporto P/B alla fine di ogni anno
Anno Rapporto P/B Cambia
Non abbastanza dati per le date fornite.
Rapporto P/B per aziende simili o concorrenti
Azienda Rapporto P/B Differenza del rapporto P/B Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.828 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 7.5116 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 8.2199 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 3.9942 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH